共 25 条
- [21] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksLANCET, 2012, 379 (9835): : 2439 - 2448Sax, Paul E.DeJesus, EdwinMills, AnthonyZolopa, AndrewCohen, CalvinWohl, DavidGallant, Joel E.Liu, Hui C.Zhong, LijieYale, KittyWhite, KirstenKearney, Brian P.Szwarcberg, JavierQuirk, ErinCheng, Andrew K.
- [22] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLANCET, 2014, 384 (9944): : 665 - 673Garon, Edward B.Ciuleanu, Tudor-EliadeArrieta, OscarPrabhash, KumarSyrigos, Konstantinos N.Goksel, TuncayPark, KeunchilGorbunova, VeraDario Kowalyszyn, RubenPikiel, JoannaCzyzewicz, GrzegorzOrlov, Sergey V.Lewanski, Conrad R.Thomas, MichaelBidoli, PaoloDakhil, ShakerGans, StevenKim, Joo-HangGrigorescu, AlexandruKaraseva, NinaReck, MartinCappuzzo, FedericoAlexandris, EkaterineSashegyi, AndreasYurasov, SergeyPerol, Maurice
- [23] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks (vol 379, pg 2439, 2012)LANCET, 2012, 380 (9843): : 730 - 730Sax, P. E.DeJesus, E.Mills, A.
- [24] Glycaemic control in Type 2 diabetes tube-fed patients after brain damage during long-term treatment with a new low carbohydrate, high monounsaturated fatty acid containing enteral formula versus a standard-like formula. A randomised, prospective, controlled, double-blind, multi-centre trialDIABETOLOGIA, 2004, 47 : A241 - A242Mayr, PMertl-Roetzer, MLauster, FPohl, MLerch, MHaslbeck, MEriksen, JRahlfs, VW
- [25] Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapya European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)CANCER, 2015, 121 (17) : 2933 - 2941Coens, Corneelvan der Graaf, Winette T. A.Blay, Jean-YvesChawla, Sant P.Judson, IanSanfilippo, RobertaManson, Stephanie C.Hodge, Rachel A.Marreaud, SandrinePrins, Judith B.Lugowska, IwonaLitiere, SaskiaBottomley, Andrew